Experienced in Waldenstrom Macroglobulinemia

Dr. Everett E. Vokes

Hematology Oncology | Urology | Hematology
The University Of Chicago
355 E Grand Ave, 
Chicago, IL 
Accepting New Patients
Offers Telehealth
Experienced in Waldenstrom Macroglobulinemia
The University Of Chicago
355 E Grand Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Everett Vokes is a Hematologist Oncology specialist and an Urologist in Chicago, Illinois. Dr. Vokes is rated as an Experienced provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Gastrostomy, and Bladder Reconstruction. Dr. Vokes is currently accepting new patients.

His clinical research consists of co-authoring 232 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Urology
Hematology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Uchicago Medicine Northwest Indiana
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
355 E Grand Ave, Chicago, IL 60611
Other Locations
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Nivolumab, Hydroxyurea, 5-Fluorouracil, Filgrastim, Cisplatin
Study Phase: Phase 2
An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial
An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial
Enrollment Status: Completed
Publish Date: September 24, 2024
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Paclitaxel albumin-stabilized nanoparticle formulation, Carboplatin, Paclitaxel, Fluorouracil, Hydroxyurea, Cisplatin
Study Phase: Phase 2
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
Enrollment Status: Terminated
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab
Study Phase: Phase 2
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer
Enrollment Status: Completed
Publish Date: April 09, 2018
Intervention Type: Drug, Procedure
Study Phase: Phase 3
View 11 Less Clinical Trials

232 Total Publications

Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
Journal: Oral oncology
Published: July 28, 2025
Similar Doctors
Distinguished in Waldenstrom Macroglobulinemia
Dr. Shuo Ma
Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Shuo Ma
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.4 miles away)
866-587-4322
Experience:
31+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shuo Ma is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ma has been practicing medicine for over 31 years and is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Distinguished in Waldenstrom Macroglobulinemia
Dr. Agne Paner
Hematology Oncology | Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Agne Paner
Hematology Oncology | Hematology | Oncology
2160 S 1st Ave, 
Maywood, IL 
 (11.4 miles away)
708-327-2206
Languages Spoken:
English
See accepted insurances

Agne Paner is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Paner is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Smoldering Multiple Myeloma, and Bone Marrow Aspiration.

Distinguished in Waldenstrom Macroglobulinemia
Dr. Ebenezer A. Kio
Hematology Oncology | Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Ebenezer A. Kio
Hematology Oncology | Hematology | Oncology

The University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (7.1 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ebenezer Kio is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Kio is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Mantle Cell Lymphoma (MCL), and Chronic Lymphocytic Leukemia (CLL). Dr. Kio is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vokes's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 9 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile